Holen Sie sich die Stockscreener-App
5.00
0.20%
-0.010
Schlusskurs vom Vortag:
$5.01
Offen:
$5.005
24-Stunden-Volumen:
11,372
Relative Volume:
0.06
Marktkapitalisierung:
$3.06M
Einnahmen:
$644.60K
Nettoeinkommen (Verlust:
$-9.87M
KGV:
-0.00597
EPS:
-837.9618
Netto-Cashflow:
$-9.02M
1W Leistung:
+10.38%
1M Leistung:
-9.58%
6M Leistung:
-56.52%
1J Leistung:
-89.60%
1-Tages-Spanne:
$4.88
$5.05
1-Wochen-Bereich:
$4.395
$5.16
52-Wochen-Spanne:
$3.58
$92.00
Biodexa Pharmaceuticals Plc Adr Stock (BDRX) Company Profile
Firmenname
Biodexa Pharmaceuticals Plc Adr
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie BDRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BDRX
Biodexa Pharmaceuticals Plc Adr
|
4.9371 | 3.15M | 644.60K | -9.87M | -9.02M | -837.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.70 | 116.04B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.46 | 75.97B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
457.57 | 61.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
898.41 | 56.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
204.34 | 43.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Biodexa Pharmaceuticals Plc Adr Stock (BDRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-02-08 | Eingeleitet | Ladenburg Thalmann | Buy |
Biodexa Pharmaceuticals Plc Adr Aktie (BDRX) Neueste Nachrichten
Biodexa enrolls first European patients in phase 3 FAP trial By Investing.com - Investing.com South Africa
[424B3] Biodexa Pharmaceuticals Plc Prospectus Filed Pursuant to Rule 424(b)(3) - Stock Titan
Biodexa activates first European site for phase 3 FAP trial By Investing.com - Investing.com India
Biodexa activates first European site for phase 3 FAP trial - Investing.com
Biodexa Pharmaceuticals plc (BDRX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Biodexa Pharmaceuticals (NASDAQ:BDRX) Stock Price Down 0.4% – What’s Next? - Defense World
[POS AM] Biodexa Pharmaceuticals Plc SEC Filing - Stock Titan
Total debt per share of Biodexa Pharmaceuticals plc Sponsored ADR – BER:5MP - TradingView
What Makes Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) a New Buy Stock - MSN
Holdings of Biodexa Pharmaceuticals Plc ADR (BDRX) are aligned with the stars - setenews.com
Biodexa receives EMA approval for phase 3 FAP treatment trial - Investing.com India
Biodexa (NASDAQ: BDRX) sets first EU enrollment for 4Q 2025 after EMA CTA approval - Stock Titan
Biodexa Pharmaceuticals (NASDAQ:BDRX) Stock Price Up 5.7% – Time to Buy? - Defense World
Biodexa Pharmaceuticals (NASDAQ:BDRX) Given Sell (E+) Rating at Weiss Ratings - Defense World
Why Did Biodexa Pharmaceuticals' Stock Drop After-Hours Despite Big Gain During Regular Trading? - inkl
Biodexa Hosts Breakfast Symposium on FAP Mechanisms and Chemoprevention at CGA‑IGC in October 2025 - Stock Titan
Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) Short Interest Update - Defense World
Short Interest in Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) Decreases By 53.3% - Defense World
Interim results for the six months ended June 30, 2025 - GlobeNewswire
Biodexa Pharmaceuticals reports 1H EPS (GBP0.0002) vs. (GBP0.001) last year - TipRanks
Biodexa says requirement for financing represents ‘material uncertainty’ - TipRanks
First Patients Enrolled: Biodexa's Breakthrough FAP Treatment Advances to Pivotal Phase 3 Trial with $35M Backing - Stock Titan
Biodexa begins phase 3 trial of FAP treatment with $20M funding By Investing.com - Investing.com South Africa
Biodexa begins phase 3 trial of FAP treatment with $20M funding - Investing.com Canada
$7 Billion Untapped Market: Biodexa's eRapa Could Be First FDA-Approved Drug for Devastating FAP Disease - Stock Titan
Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) Upgraded to Buy: What Does It Mean for the Stock? - MSN
Nanotechnology Stocks To Watch Today – September 1st - Defense World
Biodexa announces enrollment of first two patients in Phase 3 Serenta trial - MSN
Biodexa Pharmaceuticals (NASDAQ:BDRX) Trading 2.3% Higher – Time to Buy? - Defense World
Biodexa Announces Enrolment of First Patients into Pivotal - GlobeNewswire
[6-K] Biodexa Pharmaceuticals plc American Depositary Shs Current Report (Foreign Issuer) - Stock Titan
$7.3 Billion Market Opportunity: Biodexa's eRapa Could Become First-Ever Drug Treatment for FAP Cancer Risk - Stock Titan
Biodexa Pharmaceuticals (NASDAQ:BDRX) Cut to Strong Sell at Wall Street Zen - Defense World
Biodexa completes ADR ratio change to 1:100,000 ordinary shares By Investing.com - Investing.com South Africa
Biodexa Pharmaceuticals Implements ADR Ratio Change - TipRanks
ADR Ratio Change Effective | BDRX Stock News - GuruFocus
Biodexa completes ADR ratio change to 1:100,000 ordinary shares - Investing.com
Biodexa Pharmaceuticals PLC ADR ratio changes to 1:100,000. - AInvest
Biodexa Pharmaceuticals Announces ADR Ratio Change Effective July 31, 2025 - AInvest
ADR Ratio Change Effective - GlobeNewswire
Biodexa Implements Major ADR Restructuring: 10,000 to 100,000 Shares Per ADR Change Now Active - Stock Titan
Biodexa Pharmaceuticals (BDRX) Trading Halted with Pending News - GuruFocus
Biodexa advances FAP treatment with phase 3 trial initiation By Investing.com - Investing.com Nigeria
Breakthrough FAP Treatment Enters Phase 3: How Biodexa Could Transform $7B Cancer Prevention Market - Stock Titan
Biodexa advances FAP treatment with phase 3 trial initiation - Investing.com
Biodexa Pharmaceuticals Announces Reverse ADR Split to Regain Nasdaq Compliance - AInvest
Finanzdaten der Biodexa Pharmaceuticals Plc Adr-Aktie (BDRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.91%
0.98%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):